Abstract:Introduction/Background Cervical cancer is a prevalent gynecological malignancy in China, with limited treatment options for advanced stages. Despite platinum-based chemotherapy, patients with advanced cervical cancer face a median survival of only 16.8 months, emphasizing the need for alternative therapies. PIK3CA mutations are frequently observed in cervical cancer, leading to the constitutive activation of the PI3K-AKT pathway. Although PI3K inhibitors, like alpelisib (BYL719), show promise, challenges persist, including efficacy prediction and limited single-drug effectiveness. Methodology Utilizing CRISPR/Cas9 technology, we employed a negative selection strategy to identify efficacy biomarkers for PI3Kα inhibitors in cervical cancer. We knocked down KMT2D and established stable cell lines, assessing responses to BYL719 through CCK8 assays, IC50 calculations, apoptosis, and cell cycle analyses. To elucidate the mechanism, CUT&Tag combined with RNA-seq analysis was performed, exploring the impact of KMT2D on ITGB6 expression and downstream FAK Y397 phosphorylation. In vivo verification involved subcutaneous tumorigenic administration experiments in nude mice with KMT2D knockdown cell lines. Results KMT2D silencing increased BYL719 sensitivity, apoptosis, and cell cycle arrest in vitro. Overexpression of KMT2D conferred resistance. Mechanistically, KMT2D regulated ITGB6 expression, impacting FAK Y397 phosphorylation and the PI3K/AKT pathway. In vivo, KMT2D knockdown enhanced BYL719 efficacy. To address resistance, we induced PI3Kα inhibitor-resistant cell lines, revealing upregulated phosphorylation-modification-related proteins enriched in the Focal adhesion pathway. Combining BYL719 with the FAK inhibitor Defactinib reversed resistance. Conclusion Genome-wide CRISPR/Cas9 screening identified KMT2D as an efficacy biomarker for BYL719 in cervical cancer. Silencing KMT2D enhanced BYL719 sensitivity by regulating ITGB6 and FAK Y397 phosphorylation. Additionally, the combination of BYL719 and Defactinib reversed PI3Kα inhibitor resistance. This study provides insights for clinical trials, emphasizing the potential of KMT2D as a predictive marker for PI3Kα inhibitors in cervical cancer treatment. Disclosures There are no financial conflicts of interest to disclose.

Structure-Based identification of a potent KDM7A inhibitor exerts anticancer activity through transcriptionally reducing MKRN1 in taxol- resistant and -sensitive triple-negative breast cancer cells

Remodeling Tumor-Associated Macrophage for Anti-Cancer Effects by Rational Design of Irreversible Inhibition of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy

Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy Against Breast Cancer

Design, Synthesis and Structure-Activity Relationship Studies of a Focused Library of Pyrimidine Moiety with Anti-Proliferative and Anti-Metastasis Activities in Triple Negative Breast Cancer.

Discovery of Novel Thiophene [2,3-D] Pyrimidine–thiazole Derivative As Promising MNK Inhibitor to Treat Breast Cancer

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2h,4h)-dione Analogues: Development of Potent Eef2k Degraders Against Triple-Negative Breast Cancer.

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H,4 H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer

A Novel Small-Molecule Antagonizes PRMT5-mediated KLF4 Methylation for Targeted Therapy

Novel Multi‑kinase Inhibitor, T03 Inhibits Taxol‑resistant Breast Cancer.

Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and Its Antiproliferative Activity.

A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors.

Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer

An Inhibitor of KDM5 Demethylases Reduces Survival of Drug-Tolerant Cancer Cells.

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer

Pharmacological inhibition of KDM5A for cancer treatment

542 the Role and Mechanism of KMT2D to Modulate PI3Kα Inhibitor Response in Cervical Cancer Identified by CRISPR/Cas9 Genome-Wide Screening